Date: 2011-06-21
Type of information: Licensing agreement
Compound: EB66® duck embryonic stem cell line
Company: Vivalis (France) Kyoto Biken Laboratories (Japan)
Therapeutic area: Veterinary medicine
Type agreement: licensing
Action mechanism:
Disease:
Details: Vivalis and Kyoto Biken Laboratories have entered into a commercial license agreement with to produce a veterinary vaccine in Vivalis’ EB66® duck embryonic stem cell line. No Vivalis has already about 30 licenses on going, and three new licenses for the use of EB66® cell line have been signed since the beginning of 2011
Financial terms:
Latest news:
